# Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

> **NCT03742895** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 329 (actual)

## Conditions studied

- Advanced Solid Neoplasms

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03742895
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-12
- **Primary completion:** 2025-08-12
- **Final completion:** 2026-06-30
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742895, "Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03742895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*